Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	1/19/2008 3:58:14 AM
	of 3044

The company said it expects to complete enrollment in an ongoing Phase II trial testing SGN-40 as a single agent in diffuse large B-cell lymphoma (DLBCL). The drug also is in a Phase IIb trial in DLBCL in combination with Rituxan (rituximab, Genentech and Biogen Idec Inc.), and in Phase Ib studies testing SGN-40 in combination with Revlimid (lenalidomide, Celgene Corp.) in multiple myeloma and in combination with Rituxan in follicular and marginal zone NHL. Seattle Genetics and Genentech also plan to initiate this year a combination trial with Velcade (bortezomib, Millennium Pharmaceuticals Inc.) in multiple myeloma and a trial combining SGN-40 with Rituxan and Gemzar (gemcitabine, Eli Lilly & Co.) in DLBCL. bioworld.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next